Author

Jan Witowski

Observed names: J. Witowski, Witowski, Jan

OpenAlex ID: A5061549948

Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2-breast cancer

2026 · Jailan Elayoubi, Cerise Tang, et al. · medRxiv · 1

Prognostic Risk Refinement using Artificial Intelligence in HR+/HER2- Early Breast Cancer: Implications for CDK4/6 Eligibility Criteria

2026 · Nicholas P McAndrew, Cynthia Ma, et al. · medRxiv · 1

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

2026 · Park, Jungkyu, Biswas, Dhruva, et al. · arXiv (Cornell University)

A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2− Early Breast Cancer

2026 · Thomas Bachelot, Sylvie Chabaud, et al. · medRxiv

An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2-Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial

2026 · Nancy Chan, Cerise Tang, et al. · medRxiv

Causal multi-modal AI for personalized chemosensitivity prediction

2026 · Biswas, Dhruva, Berrevoets, Jeroen, et al. · arXiv (Cornell University)

Prognostic performance of an AI-based recurrence risk model in clinically low-risk HR+/HER2- early breast cancer

2026 · Cerise Tang, Dhruva Biswas, et al. · medRxiv

Real-world deployment of a multimodal artificial intelligence (AI) model for predicting response to neoadjuvant chemotherapy in early breast cancer.

2026 · Bareket Daniel, Michèle Buchinger, et al. · Journal of Clinical Oncology

Evaluating the prognostic performance of an AI-based model in clinically low-risk HR+/HER2− early breast cancer.

2026 · Dhruva Biswas, Cerise Tang, et al. · Journal of Clinical Oncology

Estimating individual benefit from adjuvant chemotherapy in hormone receptor–positive breast cancer using causal multimodal artificial intelligence.

2026 · Frederick Howard, Jad M. Abdelsattar, et al. · Journal of Clinical Oncology

Evaluating performance of an AI-based recurrence score in early breast cancer patients treated with chemoendocrine therapy: A secondary analysis of the UNIRAD trial.

2026 · Thomas Bachelot, Sylvie Chabaud, et al. · Journal of Clinical Oncology

Abstract PS3-04-04: Ai predicts response to neoadjuvant therapy in breast cancer across diverse cohorts

2026 · J. Park, F. Howard, et al. · Clinical Cancer Research

Abstract PS3-06-07: Aligning AI Recurrence Predictions with Real-world Recurrence Rates Through Survival Calibration

2026 · K. G. Zeng, J. Witowski, et al. · Clinical Cancer Research

Works count: 13

Citation count: 2

H-index: 1

I10-index: